SCHEMBL6021075

SCHEMBL6021075

C[C@H](O)C(O)(c1ccccc1)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
CYP2D6 P10635 2/20 0.57
CYP2C19 P33261 2/20 0.57
HSD17B10 Q99714 1/20 0.57
MEN1 O00255 1/20 0.50
TTR P02766 1/20 0.50
KMT2A Q03164 1/20 0.50
KCNA5 P22460 2/20 0.47
KDM4E B2RXH2 2/20 0.47
LMNA P02545 2/20 0.47
MAPK1 P28482 1/20 0.47
KCNN4 O15554 2/20 0.46
CYP1A2 P05177 2/20 0.45
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
ALOX15 P16050 1/20 0.42
ESR1 P03372 2/20 0.41
ESR2 Q92731 2/20 0.41
CYP3A4 P08684 2/20 0.41
ADRA2A P08913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL301345 1.00 ALDH1A1 (0.57) ALDH1A1CYP2D6CYP2C19HSD17B10MEN1
SCHEMBL25608886 0.89 CYP17A1 (0.54) ALDH1A1CYP2D6CYP2C19HSD17B10MEN1
SCHEMBL1819046 0.87 ALDH1A1 (0.47) ALDH1A1CYP2D6CYP2C19HSD17B10MEN1
SCHEMBL6470482 0.86 CYP2C19 (0.55) ALDH1A1CYP2D6CYP2C19HSD17B10MEN1
SCHEMBL7763320 0.85 CYP2D6 (0.50) ALDH1A1CYP2D6CYP2C19HSD17B10MEN1
SCHEMBL27480267 0.85 CYP2C19 (0.50) ALDH1A1CYP2D6CYP2C19HSD17B10MEN1
SCHEMBL8579679 0.83 ALDH1A1 (0.47) ALDH1A1CYP2D6CYP2C19HSD17B10MEN1
SCHEMBL7207713 0.83 ALDH1A1 (0.47) ALDH1A1CYP2D6CYP2C19HSD17B10MEN1
SCHEMBL5696425 0.82 ALDH1A1 (0.52) ALDH1A1CYP2D6CYP2C19HSD17B10MEN1
SCHEMBL17231876 0.82 ALDH1A1 (0.52) ALDH1A1CYP2D6CYP2C19HSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113897414-B Trace nucleic acid library construction method 湖南大地同年生物科技有限公司 2025-03-11 CN claimed
CN-113801125-B Preparation method of cyclic anhydride 安徽泰格维生素实业有限公司 2023-11-03 CN claimed
CN-113897414-A Trace nucleic acid library construction method 湖南大地同年生物科技有限公司 2022-01-07 CN claimed
CN-113801125-A Preparation method of cyclic anhydride 安徽泰格维生素实业有限公司 2021-12-17 CN claimed
US-20060074248-A1 Process for the stereoselective synthesis of lactones DSM IP ASSETS B.V. (NL) 2006-04-06 US claimed
EP-1618110-A2 A PROCESS FOR THE STEREOSELECTIVE SYNTHESIS OF LACTONES DSM IP Assets B.V. (NL) 2006-01-25 EP claimed
WO-2004094367-A2 A PROCESS FOR THE STEREOSELECTIVE SYNTHESIS OF LACTONES DSM IP ASSETS B.V. (NL) 2004-11-04 WO claimed
US-6166260-A Tandem reduction and host-guest complexation ZEELAND CHEMICALS, INC. (US) 2000-12-26 US claimed
EP-0161580-B1 PROCESS FOR THE PREPARATION OF A LACTON F. HOFFMANN-LA ROCHE AG (CH) 1990-11-07 EP claimed
EP-0161580-A2 Process for the preparation of a lacton F. HOFFMANN-LA ROCHE AG (CH) 1985-11-21 EP claimed
CN-113897414-B Trace nucleic acid library construction method 湖南大地同年生物科技有限公司 2025-03-11 CN disclosed
CN-114560865-B Continuous flow synthesis method of (3 aS,6 aR) -lactone 复旦大学 2024-02-02 CN disclosed
CN-113801125-B Preparation method of cyclic anhydride 安徽泰格维生素实业有限公司 2023-11-03 CN disclosed
CN-113549084-B Method for stereoselectively synthesizing chiral lactone 杭州科兴生物化工有限公司 2023-02-28 CN disclosed
CN-113121549-B Method for stereoselectively synthesizing chiral lactone, chiral compound and application thereof 江西天新药业股份有限公司 2022-08-26 CN disclosed
US-6166260-A Tandem reduction and host-guest complexation ZEELAND CHEMICALS, INC. (US) 2000-12-26 US disclosed
US-6093826-A Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines LIGAND PHARMACEUTICALS INCORPORATED (US) 2000-07-25 US disclosed
EP-0161580-B1 PROCESS FOR THE PREPARATION OF A LACTON F. HOFFMANN-LA ROCHE AG (CH) 1990-11-07 EP disclosed
US-4687859-A CHEMICAL INTERMEDIATE FOR BIOTIN HOFFMANN-LA ROCHE INC. (US) 1987-08-18 US disclosed
US-4628120-A REARRANGEMENTS USING ORGANOALUMINUM COMPOUNDS TOYO STAUFFER CHEMICAL CO., LTD. (JP) 1986-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074248-A1 Process for the stereoselective synthesis of lactones COASY, ADSL, ALAD ALDH1A1 350/4885CYP2D6 1056/4885CYP2C19 688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.